Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.
Our first novel microbiome modulator, RP-G28, is currently under development for the treatment of lactose intolerance.
- RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.
- Our leadership team has extensive biotechnology/pharmaceutical expertise in discovering, developing, licensing and commercializing therapeutic products.
Among our strategies is to establish Ritter Pharmaceuticals as a leader in developing therapeutics that modulate the human gut microbiome.